The sirtuin inhibitor cambinol reduces intracellular glucosylceramide with ceramide accumulation by inhibiting glucosylceramide synthase

References

• Aerts JMFG, Artola M, van Eijk M, et al. Glycosphingolipids and infection. Potential new therapeutic avenues. Front Cell Dev Biol. 2019;7:324.
   PubMed Web of Science ®Google Scholar
• Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci. 2007;64:2270–2284.
   PubMed Web of Science ®Google Scholar
• Jennemann R, Gröne HJ. Cell-specific in vivo functions of glycosphingolipids: lessons from genetic deletions of enzymes involved in glycosphingolipid synthesis. Prog Lipid Res. 2013;52:231–248.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Kohyama-Koganeya A, Hirabayashi Y. New insights on glucosylated lipids: metabolism and functions. Biochim Biophys Acta. 2013;1831:1475–1485.
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263–1271.
   PubMed Web of Science ®Google Scholar
• Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11:986–998.
   PubMed Web of Science ®Google Scholar
• Natoli TA, Modur V, Ibraghimov-Beskrovnaya O. Glycosphingolipid metabolism and polycystic kidney disease. Cell Signal. 2020;69:109526.
   PubMed Web of Science ®Google Scholar
• Huebecker M, Moloney EB, Van Der Spoel AC, et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease. Mol Neurodegener. 2019;14:40.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Hirabayashi Y. AMP-activated protein kinase suppresses biosynthesis of glucosylceramide by reducing intracellular sugar nucleotides. J Biol Chem. 2015;290:18245–18260.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Ito M, Hirabayashi Y. Regulation of glucosylceramide synthesis by Golgi-localized phosphoinositide. Biochem Biophys Res Commun. 2018;499:1011–1018.
   PubMed Web of Science ®Google Scholar
• Dai H, Sinclair DA, Ellis JL, et al. Sirtuin activators and inhibitors: promises, achievements, and challenges. Pharmacol Ther. 2018;188:140–154.
   PubMed Web of Science ®Google Scholar
• Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24:464–471.
   PubMed Web of Science ®Google Scholar
• Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006;66:4368–4377.
   PubMed Web of Science ®Google Scholar
• Shayman JA, Larsen SD. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases. J Lipid Res. 2014;55:1215–1225.
   PubMed Web of Science ®Google Scholar
• Loewith R, Riezman H, Winssinger N. Sphingolipids and membrane targets for therapeutics. Curr Opin Chem Biol. 2019;50:19–28.
   PubMed Web of Science ®Google Scholar
• Wennekes T, Van Den Berg RJBHN, Donker W, et al. Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem. 2007;72:1088–1097.
   PubMed Web of Science ®Google Scholar
• Shayman JA. Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective. Am J Physiol - Ren Physiol. 2015;309:F996–F999.
   PubMed Web of Science ®Google Scholar
• Shayman JA, Lee L, Abe A, et al. Inhibitors of glucosylceramide synthase. Methods Enzymol. 2000;311:373–387.
   PubMed Web of Science ®Google Scholar
• Inokuchi J, Radin NS. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J Lipid Res. 1987;28:565–571.
   PubMed Web of Science ®Google Scholar
• Inokuchi J, Ode T, Hara-Yokoyama M. Pharmacological modulation of glycosphingolipid metabolism. Methods Mol Biol. 2018;1804:401–410.
   PubMedGoogle Scholar
• Watanabe S, Endo S, Oshima E, et al. Glycosphingolipid synthesis in cerebellar purkinje neurons: roles in myelin formation and axonal homeostasis. Glia. 2010;58:1197–1207.
   PubMed Web of Science ®Google Scholar
• Gupta V, Patwardhan GA, Zhang QJ, et al. Direct quantitative determination of ceramide glycosylation in vivo: A new approach to evaluate cellular enzyme activity of glucosylceramide synthase. J Lipid Res. 2010;51:866–874.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Horibata Y, Sakaguchi K, et al. A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates. Anal Biochem. 2005;345:181–186.
   PubMed Web of Science ®Google Scholar
• Shaner RL, Allegood JC, Park H, et al. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J Lipid Res. 2009;50:1692–1707.
   PubMed Web of Science ®Google Scholar
• Price NL, Gomes AP, Ling AJY, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15:675–690.
   PubMed Web of Science ®Google Scholar
• Morad SAF, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013;13:51–65.
   PubMed Web of Science ®Google Scholar
• Grozinger CM, Chao ED, Blackwell HE, et al. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001;276:38837–38843.
   PubMed Web of Science ®Google Scholar
• Shinoda T, Shinya N, Ito K, et al. Cell-free methods to produce structurally intact mammalian membrane proteins. Sci Rep. 2016;6:1–15.
   PubMed Web of Science ®Google Scholar
• Wu K, Marks DL, Watanabe R, et al. Histidine-193 of rat glucosylceramide synthase resides in a UDP-glucose- and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-morpholinopropan-1-ol)-binding region: a biochemical and mutational study. Biochem J. 1999;341:395.
   PubMed Web of Science ®Google Scholar
• Casson L, Howell L, Mathews LA, et al. Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. Starczynowski DT, editor. PLoS One. 2013;8:e54525.
   PubMed Web of Science ®Google Scholar
• Figuera-Losada M, Stathis M, Dorskind JM, et al. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties. PLoS One. 2015;10:e0124481.
   PubMed Web of Science ®Google Scholar
• Lienert F, Mohn F, Tiwari VK, et al. Genomic prevalence of heterochromatic H3K9me2 and transcription do not discriminate pluripotent from terminally differentiated cells. Reik W, editor. PLoS Genet. 2011;7:e1002090.
   PubMed Web of Science ®Google Scholar
• Thul PJ, Akesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol. 2008;64:514–522.
   PubMed Web of Science ®Google Scholar
• Shayman JA. ELIGLUSTAT TARTRATE: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future. 2010;35:613–620.
   PubMed Web of Science ®Google Scholar
• Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A. 2011;108:12101–12106.
   PubMed Web of Science ®Google Scholar
• Bilousova T, Elias C, Miyoshi E, et al. Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2. Biochem Biophys Res Commun. 2018;499:751–757.
   PubMed Web of Science ®Google Scholar